Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 12/20 | 0.40 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17152399 | 0.83 | MEN1 (0.50) | MEN1KMT2ADPP7TLR2RRM1 | |
| SCHEMBL17167980 | 0.81 | DPP7 (0.51) | MEN1KMT2ADPP7TLR2RRM1 | |
| SCHEMBL22621226 | 0.81 | TLR2 (0.47) | MEN1KMT2ADPP7TLR2RRM1 | |
| SCHEMBL10051021 | 0.78 | DPP7 (0.38) | DPP7RRM1S1PR2S1PR1S1PR3 | |
| SCHEMBL18906348 | 0.77 | MEN1 (0.39) | MEN1KMT2ATLR2 | |
| SCHEMBL18906341 | 0.77 | MEN1 (0.39) | MEN1KMT2ATLR2 | |
| SCHEMBL22398650 | 0.77 | MEN1 (0.47) | MEN1KMT2ADPP7TLR2 | |
| SCHEMBL22398651 | 0.77 | MEN1 (0.47) | MEN1KMT2ADPP7TLR2 | |
| SCHEMBL22687577 | 0.76 | MEN1 (0.43) | MEN1KMT2ATLR2 | |
| SCHEMBL24164680 | 0.76 | ANPEP (0.50) | DPP7RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | LUMIPHORE, INC. (US) | 2019-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | CLTB, CLTA, EPCAM | MEN1 2259/4885KMT2A 3740/4885DPP7 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.